Console & Associates, P.C. Investigates Zynex, Inc. Securities Class Action Lawsuit

Investors who purchased Zynex, Inc. securities between March 13, 2023 and March 11, 2025 are encouraged to contact Console & Associates, P.C. regarding the May 19, 2025 lead plaintiff deadline.

MARLTON, N.J., March 25, 2025 /PRNewswire/ -- Console & Associates, P.C. announced it is investigating a securities class action lawsuit filed in federal court on behalf of purchasers of Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, inclusive (the "Class Period").

Investors who purchased Zynex securities during the Class Period may be entitled to seek appointment as lead plaintiff in this case. The lead plaintiff will represent other class members in directing the litigation and can potentially secure a more favorable recovery. Interested investors must file their motion with the Court no later than May 19, 2025.

Zynex, Inc. develops, manufactures, and markets medical devices for pain management and rehabilitation. The Company specializes in electrotherapy technology for non-invasive pain relief and muscle stimulation.

According to the complaint, during March 13, 2023 and March 11, 2025, defendants made materially false and misleading statements and/or failed to disclose adverse information regarding Zynex's business and operations. Specifically, defendants allegedly failed to disclose that:

1. Zynex shipped products, including electrodes, in excess of patient need;
2. The Company inflated its revenue through these excessive shipment practices;
3. Zynex's practice of filing questionable claims drew scrutiny from insurers, including Tricare;
4. As a result, Zynex faced significant risk of adverse consequences, including potential removal from insurer networks and federal government penalties;
5. These practices made defendants' statements about Zynex's business, operations, and prospects materially misleading and/or lacking reasonable basis.

On March 11, 2025, Zynex announced its fourth quarter and full year 2024 financial results, revealing a significant revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." The Company also disclosed that "Tricare has temporarily suspended payments as they review prior claims." Tricare reportedly represents approximately 20-25% of Zynex's annual revenue.

Following this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025.

If you purchased Zynex securities during the Class Period and wish to serve as lead plaintiff in this case, you must file a motion with the Court no later than May 19, 2025. For more information about your legal rights and potential remedies, please complete our contact form.

There is no cost or obligation to you. The case is being pursued on a contingency fee basis, which means there will be no fees or costs to you if there is no recovery.

For over 30 years, the securities attorneys at Console & Associates, P.C. have been representing individuals harmed by corporate negligence.

This press release may be considered attorney advertising in some jurisdictions under applicable law and ethical rules.

Console & Associates, P.C.
866-778-5500
[email protected]

SOURCE Console & Associates, P.C.